The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 28, 2020

Filed:

Sep. 08, 2016
Applicants:

Bristol-myers Squibb Company, Princeton, NJ (US);

Domantis Limited, Brentford, Middlesex, GB;

Inventors:

Anish Suri, Ekeren, BE;

Steven Sheriff, Princeton, NJ (US);

Suzanne Suchard, Portland, OR (US);

Aaron Yamniuk, Lawrenceville, NJ (US);

Stanley Krystek, Ringoes, NJ (US);

James Tamura, Yardley, PA (US);

James Bryson, Langhorne, PA (US);

Steven Grant, Swaffham Prior, GB;

Philip Drew, Histon, GB;

Assignees:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Domantis Limited, Brentford, Middlesex, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/13 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/18 (2013.01); C07K 16/2833 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).


Find Patent Forward Citations

Loading…